Randomised, phase 1 evaluation of the safety, tolerability, pharmacokinetics and...

연구 요약

Randomised, phase 1 evaluation of the safety, tolerability, pharmacokinetics and pharmacodynamics of iptacopan in healthy volunteers.

British journal of pharmacology 학술지에 발표된 이 연구는 Baltcheva I, Junge G, Kulmatycki K 외 연구팀이 수행하였습니다.

이 연구는 'Randomised, phase 1 evaluation of the safety, tolerability, pharmacokinetics and pharmacodynamics of iptacopan in healthy volunteers.'에 대한 과학적 분석을 제공합니다.

핵심 내용

BACKGROUND AND PURPOSE: Overactivation of the alternative pathway (AP) underlies several diseases. Iptacopan is an oral, first-in-class, highly potent specific inhibitor of factor B, a key AP protease. EXPERIMENTAL APPROACH: The analysis included data from two phase 1 randomised, volunteer-blinded, placebo-controlled studies: Study 1, a single ascending dose (SAD; 5-400 mg), multiple ascending dose (MAD; 25-200 mg twice daily), and food effect study of iptacopan in healthy volunteers; Study 2, a SAD (25-400 mg) study of iptacopan in healthy Japanese males. The objectives were to evaluate the safety and tolerability of iptacopan, and the pharmacokinetics/pharmacodynamics of SAD and MAD doses. KEY RESULTS: In Study 1 (n = 100) and Study 2 (n = 30), iptacopan was rapidly absorbed; pharmacokinetic variability was low, with a half-life between 18.4 and 25.0 h across steady-state MAD doses, and iptacopan exhibited target-mediated drug disposition behaviour. Japanese and non-Japanese healthy volunteers had similar pharmacokinetics/pharmacodynamics. Food intake did not affect pharmacokinetics. Iptacopan 200 mg twice daily showed the highest and most persistent AP inhibition; ~67% AP inhibition remained 24 h after the last dose, while ex vivo classical complement pathway activation was not impaired. This dose also provided the highest proportion of volunteers achieving EC90 values for the complement biomarkers Wieslab® assay in serum, plasma Bb and sC5b-9. Iptacopan was well tolerated across doses. CONCLUSIONS AND IMPLICATIONS: These results characterise the pharmacokinetics/pharmacodynamics of iptacopan in healthy volunteers; the data helped build semi-mechanistic population pharmacokinetic/pharmacodynamic models, which guided the accelerated clinical development of iptacopan.

일반인을 위한 해석

구체적인 실천 사항은 담당 의사 또는 약사와 상담하시기 바랍니다.

실천 사항

• 현재 복용 중인 약물이나 영양제에 대해 궁금한 점이 있다면 담당 의사 또는 약사와 상담하시기 바랍니다
• 약물이나 영양제의 용법·용량을 임의로 변경하지 마세요
• 이상 반응이 나타나면 즉시 전문가에게 문의하세요

의사/약사의 전문적 판단을 대체하지 않습니다 (PMID: 41701988)